Sir,
Hemoglobin estimation of blood donors is performed to prevent anemic donors from donating blood and ensuring a good quality of packed red blood cell component. Several devices are presently available for hemoglobin estimation of blood donors as a screening test before blood donation. [1] The desirable features of a device intended for mass screening include high accuracy, precision, rapidity, and ease of operation. [2] In our part of country, there is a wide variation in temperature conditions. Thus, any device which has to be used for hemoglobin screening in outdoor blood donation camps should be able to give its optimum performance even at highest temperature range in that region. In this study, we have compared the performance of HemoCue Hb301 System at indoor temperatures (18-22°C) and outdoor temperatures (>35°C) in the month of July 2014.
Ethylenediaminetetraacetic acid anticoagulated venous samples of 100 patients which were sent for hemoglobin estimation were tested by manual cyanmethemoglobin method which was standardized using commercially available standards (Span diagnostics, Surat, India) as a routine testing method. For comparing the accuracy, these were tested by HemoCue Hb301 System both at in the air-conditioned departmental laboratory (T1) and at outdoor work station (T2) by the same operator. The samples initially placed at T1 for 1 h were tested by cyanmethemoglobin method and HemoCue Hb301 System. These were then kept at T2 for 1 h before retesting with HemoCue Hb301 System after ensuring their physical integrity. For comparing the precision, 5 samples tested by cyanmethemoglobin method were taken. Each was retested 10 times by HemoCue Hb301 System both at T1 and T2.
The results obtained are summarized in Figure 1 and Table 1 .
HemoCue Hb301 is a quantitative point of care system based on photometric detection of hemoglobin level. A previous study has evaluated its performance against previous HemoCueHb 201+ system in diagnosing anemia of pregnancy and found it sufficiently precise and accurate. [3] The system is designed to operate at 10-40°C [4] but there are no studies to the best of our knowledge, for evaluating its performance at varied temperature conditions. The device has shown good accuracy at both T1 (correlation coefficient r = 0.903) as well as T2 (correlation coefficient r = 0.893). The precision of measurement was also good at both the temperatures with coefficient of variation ranging from 0.060 to 0.094 at T1 and from 0.041 to 0.085 at T2. Since the process of validation was performed before installation of the equipment in the department, it also allowed a chance for hands-on training of the technical staff. We conclude that HemoCue Hb301 system is adequately apt for both routine uses and use in outdoor blood donation camps.
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Letter to the Editor Letters to the Editor A 57-year-old female, Para 4, from Kenya, was referred to our hospital as a case of recurrent Carcinoma left breast stage IV for 3 rd line chemotherapy. She had a history of few episodes of transfusion 6 months before admission to our hospital. Historical records showed her blood group as "B-Positive."
On admission, patient's hemoglobin (Hb) was 6.6 g/dl, and she received 4 units of compatible packed red cells (PRCs) transfusion which was uneventful. After a week, another blood request was received for 2 units of PRC due to low Hb 7.0 g/dl. Patient blood group was done using automated platform (Autovue Innova For confirmation of Rh group, her blood group was repeated using conventional tube method using monoclonal eryclone anti-D (IgM and IgG + IgM) (Tulip Diagnostics, India), which showed 4+ reaction. B-Negative units were crossmatch compatible were transfused, and the patient was discharged with Hb 9.4 g% with stable status. On review of our records, we found that antibody screening was negative at the time of admission and all crossmatches were compatible. We also noticed that there was the inadequate rise of Hb from 6.6 to 8.0 g/dl after 4 units of transfusion which subsequently fell to 7 g/dl in week duration. However, other hemolytic investigation parameters were not available. There was no history of passive administration of anti-D.
The history of 4 PRC transfusions a week before, rapid fall of Hb, development of positive DAT with confirmation of anti-D in the eluate, incompatibility with all B-positive units and compatibility with Rh negative units confirmed DHTR. The samples were sent for partial D-confirmation and Rh genotype to a reference laboratory in South India. However, it could not be confirmed due to inadequate sample.
DHTR is defined as the posttransfusion finding of a positive DAT and a newly developed RBC alloantibody with clinical signs of hemolysis. DHTR may sometimes manifest as an inadequate rise of posttransfusion Hb level or unexplained fall in Hb after a transfusion.
Partial D has a significant implication in transfusion and pregnancy. Individuals with Partial D have missing portions of D antigen and can develop anti-D antibody if exposed to missing epitopes. [1] A case reported by Ipe et al. on severe hemolytic transfusion reaction in sickle cell disease was due to anti-D in a RhD positive patient. [2] Her Rh genotype revealed homozygosity for RHD*DAU4 that encodes partial D antigen.
This case highlights that some cases of partial-D can be missed during routine serological Rh testing and can lead to anti-D alloimmunization. They should be distinguished serologically by a pattern of reactivity using advance partial D typing kit or monoclonal antisera and by Rh genotyping. Therefore, an
